We studied the effect of 3 antidepressant treatments on outcomes (depressive severity, medication tolerability, and psychosocial functioning) in depressed patients having comorbid general medical conditions in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial.
INTRODUCTION
M ajor depressive disorder (MDD) is a psychiatric disorder that is commonly found in patients with a wide range of general medical conditions and that may have a substantial impact on patient functioning. Most of these patients with MDD have a recurrent course (>1 episode), a chronic course (an episode lasting >2 years), or both 1 with incomplete recovery between episodes. 2, 3 This common unremitting course of depression is associated with a signifi cantly worse prognosis and disability. [4] [5] [6] In 2004, the World Health Organization's Global Burden of Disease project ranked unipolar depression (MDD) as the third leading cause of disease burden (in terms of disability-adjusted life-years) worldwide and the leading cause in middle-and high-income countries. 7 The relationship between general medical conditions and comorbid depression is well documented in the literature. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 21 Assessment is challenging because the symptoms of a primary general medical condition and the related medical treatments (ie, medication adverse effects)-for example, low energy, disturbances in sleep, changes in appetite/weight, and perhaps secondary symptoms such as avolition, apathy, and anhedoniaoverlap with the diagnostic symptoms of MDD. [22] [23] [24] [25] Traditional treatments for depression are not as effective in patients with general medical conditions. 26, 27 Specifi cally, the more such conditions a patient has, the worse the prognosis for the treatment of depressive symptoms. We explored the relationship between general medical conditions and comorbid depression in a large consecutive series of patients recruited from both primary care and psychiatric practices who entered the Combining Medications to Enhance Depression Outcomes (CO-MED) study's depression treatment protocol (http://www.co-med.org). 28 The fi ndings reported here address the following questions: (1) Are there differences in overall antidepressant treatment outcomes (in terms of depressive symptom severity, medication tolerability, psychosocial functioning) based on the number of general medical conditions present? and (2) Are there differences in how patients with general medical conditions (0, 1, 2, ≥3) and comorbid MDD respond (in terms of depressive symptom severity, medication tolerability, psychosocial functioning) to traditional antidepressant monotherapy vs combination therapy.
METHODS

Study Overview
The CO-MED study lasted 7 months, consisting of 12 weeks of acute care and 16 weeks of follow-up treatment. It was a multisite, single-blind, randomized trial that compared the effi cacy of traditional selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) vs that of 2 antidepressant medication combinations (escitalopram plus bupropion-SR, and venlafaxine-XR plus mirtazapine) in patients with chronic and/or recurrent, nonpsychotic MDD. 28 Patients were blinded, but the clinical research coordinators and physicians were not to maximize safety and to allow physicians to make informed fl exible dosing decisions. Escitalopram was selected as a representative SSRI used for monotherapy, the most common fi rst-step medication treatment option. Bupropion was included in the study as a combination agent because it is a dopamine and norepinephrine modulator 29 widely used to augment SSRIs. 30, 31 The second combination of venlafaxine-XR plus mirtazapine was selected because in combination, these medications affect all 3 major neurotransmitter systems by mechanisms that differ from those of escitalopram plus bupropion-SR. 32 Patients with and without general medical conditions were randomly assigned to the 3 treatment arms in balanced fashion. The study recruited 665 outpatients with MDD, 335 of whom were being treated for at least 1 general medical condition, from 6 primary care and 9 psychiatric care sites across the Unites States. Study visits were planned at baseline and weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 , and 28. The research protocol was approved and monitored by the institutional review boards of the University of Texas Southwestern Medical Center at Dallas, the University of Pittsburgh, and each participating regional center. The study was also monitored by an independent data safety and monitoring board.
Participants
Broad inclusion and minimal exclusion criteria were used to ensure a representative participant sample. Patients with and without general medical conditions were enrolled; however, the conditions had to be medically stable as reported by their primary treating physician. Enrollees were outpatients aged 18 to 75 years who met Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) (DSM-IV-TR) 33 criteria for nonpsychotic MDD that was either recurrent (≥1 prior major depressive episode) or chronic (current major depressive episode present for ≥2 years) based on a clinical interview and the Mini International Neuropsychiatric Interview (MINI). 34 Eligibility also required that the index episode had to be ongoing for at least 2 months, and that patients have a score of at least 16 on the 17-item Hamilton Rating Scale for Depression. 35 A full listing of exclusion criteria is available on the CO-MED Web site (http://www.co-med.org).
Antidepressant Treatments
The trial used measurement-based care to enable personally tailored and vigorous antidepressant dosing. 36 Dosage adjustments were based on symptom severity using the 16-item Quick Inventory of Depressive Symptomatology-Clinician rated (QIDS-C 16 ) 37 and tolerability was assessed using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER), 38 given in Supplemental Appendix 1 (available at http://www. annfammed.org/content/10/1/23/suppl/DC1), and the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry (SAFTEE-SI) 39 obtained at each treatment visit.
Patients were stratifi ed by clinical site and randomly assigned to 3 treatment groups in 1:1:1 ratio using a Web-based randomization system. 40 Dosing schedules were based on previous effi cacy and tolerability data. [41] [42] [43] [44] Doses were increased only in the context of acceptable adverse effects. Patients could exit the study if they experienced unacceptable or intolerable adverse effects that could not be resolved with dose reduction or medication treatment.
Escitalopram Plus Placebo
Escitalopram dosing started at 10 mg/d. At week 2, 1 placebo capsule was added. At week 4 and beyond, if a patient's QIDS-C 16 score was greater than 5 (adverse effects allowing), the escitalopram dose could be increased to 20 mg/d (maximum dose) and the placebo dose could be increased to 2 capsules.
Bupropion-SR Plus Escitalopram
Bupropion-SR was started at 150 mg/d, and increased to 300 mg/d after 1 week. At the week 2 visit, blinded escitalopram 10 mg/d was added. At week 4 and beyond, if a patient's QIDS-C 16 score was greater than 5 (adverse effects allowing), the bupropion-SR dose could be increased to 400 mg/d (maximum dose), and the escitalopram dose could be increased to 20 mg/d.
Venlafaxine-XR Plus Mirtazapine
Venlafaxine-XR was started at 37.5 mg/d for 3 days and then increased to 75 mg/d. At week 1, the venlafaxine-XR dose was increased to 150 mg/d. At week 2, blinded mirtazapine 15 mg/d was added. At week 4 and beyond, if a patient's QIDS-C 16 score was greater than 5 (adverse effects allowing), the venlafaxine-XR dose could be increased to 225 mg/d, then again at a subsequent visit to 300 mg/d (maximum dose); in a similar fashion, the mirtazapine dose could be increased to 30 mg/d, then to 45 mg/d (maximum dose).
Measures
Patients' social, demographic, and clinical (medical and psychiatric) features were collected at baseline using standard forms. The clinician-rated MINI was used to evaluate mood disorders and screen for psychosis, and the self-report Psychiatric Diagnostic Screening Questionnaire 45 was used to established the presence of anxiety disorders, substance use disorders, eating disorders, and hypochondriasis. 46 Suicidal risk was assessed with the Concise Health Risk Tracking tool, given in Supplemental Appendix 2 (available at http://www.annfammed.org/content/10/1/23/ suppl/DC1). All CO-MED clinical research coordinators were certifi ed to administer the clinician-rated assessment used for screening, baseline, and regular study visits. The training and certifi cation consisted of 3 steps: (1) didactic training, (2) interrater reliability certifi cation, and (3) written examination (see the CO-MED Clinical Procedures Manual for details, http://www. co-med.org).
General medical comorbidity burden was quantifi ed using the Self-Administered Comorbidity Questionnaire, a self-report that assesses the presence of medical problems, their severity, and whether the condition limits functioning. 47 The medical conditions specifi ed include heart disease, high blood pressure, lung disease, diabetes, gastrointestinal tract disorders, kidney disease, liver disease, anemia or other blood disease, cancer, arthritis, thyroid disease, and chronic back pain. Respondents have the option of adding 3 additional conditions. An individual can receive a maximum of 3 points for each medical condition (1 point for its presence, 1 point for its treatment, and 1 point if it limits activities). For this study, we defi ned a general medical condition as one that was present and being treated.
Outcome assessments were collected at baseline and at all subsequent treatment visits. The primary outcome, depressive symptom severity, was based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR 16 ), given in Supplemental Appendix 3 (available at http://www.annfammed. org/content/10/1/23/suppl/DC1). 37 Secondary outcomes of tolerability as measured by the FIBSER and SAFTEE-SI, and social and occupational functioning as measured by the Work and Social Adjustment Scale (WSAS), 48 were collected at each clinic visit through the entire study period.
Statistical Analyses
The CO-MED study was powered to detect differences between the 3 antidepressant treatment arms. Power estimates indicated that 220 patients per group would provide adequate power (.80, with α = .05) to detect a 12.8% difference between the combination treatments and monotherapy during the acute phase, and 11.2% during the continuation phase. Power estimates for the planned secondary analysis of treatments stratifi ed by number of general medical conditions were not used to determine sample size. We computed descriptive statistics, including measures of central tendency and dispersion, for continuous data and estimated frequency distributions for categorical data. The appropriate parametric test (ie, t test) or nonparametric tests (ie, χ 2 , Wilcoxon tests) were used to ensure a balanced distribution of the social, demographic, psychiatric, and medical characteristics among patients with and without general medical conditions. At 12 and 28 weeks, we compared unadjusted and adjusted outcomes among patients with 0, 1, 2, and 3 or more general medical conditions using regression models. The type of regression models varied by outcome and included linear regression, logistic regression, ordinal logistic regression, and negative binomial regression models. Potential confounders were identifi ed using a stepwise logistic regression model with an indicator of general medical conditions as the outcome and all other baseline characteristics as independent variables. Those variables that remained in the fi nal stepwise model were considered as potential confounders in the adjusted models. The moderating effect of general medical conditions on treatment was evaluated on 2 outcomes, severity of depression (QIDS-SR 16 ), and adverse effect burden (FIB-SER burden), at 12 and 28 weeks. For severity of depression, we fi t a linear regression model; for adverse effect burden, we fi t an ordinal logistic regression model. Both models included main effects for treatment and general medical conditions, as well as the 2-way interaction between treatment and general medical conditions. All analyses are considered to be exploratory in nature, and a type I error or P value of less than .05 was used as a threshold to identify statistical signifi cance. A threshold of P less than .0083 was used to identify statistical signifi cance of post hoc comparisons in the adjusted models.
RESULTS
Patient Characteristics
Of the 665 evaluable patients, 328 (49.5%) reported having no general medical conditions, 158 (23.8%) reported having 1, 98 (14.8%) reported having 2, and 79 (11.9%) reported having at least 3. (Two participants did not complete the SCQ.) There were several signifi cant differences between participants according to the number of general medical conditions (Table  1) . Patients with such conditions more often sought treatment in primary care vs psychiatric care settings. African American patients more commonly had 3 or more conditions. The frequency of single and multiple conditions increased with age. Years of education were inversely related to the number of reported conditions. Patients with 3 or more conditions had signifi cantly greater social and occupational impairment. Those with conditions had a later age of onset of depression. Patients with 2 or more conditions reported a signifi cantly longer current depressive episode. The incidence of chronic depression (defi ned as a current episode present for ≥2 years) increased as the number of conditions increased; however, the level of depressive severity did not differ between groups having different numbers of conditions.
Outcomes by Number of Medical Conditions
We found limited differences in overall MDD treatment outcomes according to the number of general medical conditions patients had (Table 2 ). Patients with 3 or more conditions reported higher rates of impairment in social and occupational functioning (WSAS) at baseline and week 12, but not at week 28. We found no signifi cant differences in symptom severity or tolerability between the groups having different numbers of conditions at weeks 12 and 28.
Outcomes by Antidepressant Treatment
We did not fi nd any differences in outcomes between antidepressant monotherapy and either of the antidepressant combination therapies, regardless of the number of general medical conditions a patient had (Table 3) . Specifically, within each group having a given number of conditions, the 3 treatments did not differ signifi cantly with respect to any of the measures of effi cacy or tolerability assessed, at either week 12 or week 28.
DISCUSSION
Past studies have suggested that patients with general medical conditions are less responsive to antidepressant treatment. [49] [50] [51] [52] [53] [54] [55] [56] Our fi nding of an almost complete lack of statistical differences in outcome measures (efficacy and tolerability) between patients with differing numbers of conditions may, however, indicate that patients with and without such conditions can receive equally safe and effective treatment for their MDD with antidepressant medications without risk of additional adverse effects or antidepressant intolerability. Additionally, our fi nding of a lack of statistical differences in outcome measures between patients stratifi ed by number of conditions and treatment received indicates that, as assessed in our sample, combination antidepressant therapy had no additional benefi t over SSRI monotherapy for patients with general medical conditions and comorbid, chronic or recurrent MDD.
Treatment programs and guidelines have been developed, studied, and widely disseminated specifically targeting the treatment of MDD in primary care settings. [57] [58] [59] [60] [61] Past studies have identifi ed barriers to the adoption and integration of depression screening and treatment guidelines in primary care settings. 62 If depression treatment guidelines are implemented, however, outpatient treatment outcomes for depres- Not surprisingly, participants with general medical conditions and comorbid MDD were more likely to be treated for depression by their primary care physician than a psychiatric care professional. This greater likelihood of treatment in primary care could occur for a variety of reasons, the most obvious being that patients with general medical conditions and comorbid MDD may prefer to be treated by a single physician rather than use a separate mental health professional for their depression. Our study's fi ndings suggest that when comparing outcomes between primary and specialty care settings, the number of general medical conditions may need to be adjusted for in the fi nal analysis. The baseline clinical distinctions associated with the presence of single and multiple general medical conditions in patients with comorbid MDD were Notes: WSAS scores range from 0 to 40, with higher scores indicating greater levels of impairment. SCQ scores range from 0 to 45, with higher scores indicating greater number of disorders and greater levels of impairment. QIDS-SR16 scores range from 0 to 27, with higher scores indicating greater levels of depression. FIBSER scores range from 0 to 6 for each of the indexes.
a Adjusted for treatment, age, education, employment, age at fi rst episode, body mass index, and systolic blood pressure (see Supplemental Table 1, available not novel, with increased age being more frequently associated with the presence of such conditions, and the presence of an increasing number of conditions being associated with greater social and occupational impairment. Consistent with previous fi ndings, 64 participants with more general medical conditions were more likely to have chronic depression, a more severe form of depression. This association raises the possibility that a greater physical disease burden leads to a greater psychiatric disease burden. With age, physical disease burden (number of general medical conditions) almost inevitably increases, which may leave patients more vulnerable to mood and anxiety symptoms. One interpretation, based on the later age of onset of MDD in patients with multiple general medical conditions, is that the addition of physical disease burden may be involved in the onset of MDD in vulnerable individuals. Another possibility is that general medical conditions lead to increased medical evaluations, giving rise to a higher probability for the recognition of somatic and nonsomatic MDD symptoms. As treatment guidelines for patients with general medical conditions and long-standing or recurrent depression are lacking, the best clinical decision may be to begin treatment with SSRI monotherapy given an a priori evaluation of predicted compatibility with concomitant medications, and then proceed to a trial of combination medications as needed.
The interpretation of the fi nding of difference in race is unclear and may be unique to the study sample. Interestingly, participants with more education had fewer general medical conditions, suggesting that education may have some protective impact in patients with depression. Perhaps education aids in providing better self-care and improved access to medical treatment, resulting in a reduction in the development of preventable conditions.
Our study had several limitations. The number of general medical conditions by antidepressant treatment was a planned secondary analysis; however, the granularity limits the statistical power of between-group comparisons. General medical conditions were self-reported. Patients had chronic or recurrent MDD, or both, and may have had greater antidepressant treatment resistance than patients seen for a fi rst episode of depression. Physicians and clinical research coordinators were not blinded to group affi liation, and as such, patients may have been inadvertently provided information leading to some degree of unblinding, although there is no evidence of this in the outcomes. Patients were recruited from primary care and psychiatric specialty care clinics, as opposed to internal medicine specialty clinics, and we excluded those not medically stable, not receiving adequate treatments for their general medical conditions, or both. It is possible that patients with more severe general medical conditions may have a differential outcome or tolerability profi le if treated with antidepressant monotherapy as opposed to combination therapy. All patients received antidepressants in dosages in accord with current Food and Drug Administration guidelines; differential treatment response may become more apparent if medications are given at higher dosages. 65 Additionally, several of the symptom criteria for MDD (decreased energy, sleep and appetite irregularities) may be infl uenced by general medical conditions. The overlap in symptoms between MDD and these conditions may also be partially responsible for an increase in diagnosis of MDD in those with general medical conditions, as well as an increase in depressive severity scores.
In conclusion, patients with and without general medical conditions can be safely and effectively treated for MDD with antidepressant medications with no additional adverse effect or tolerability burden for the former. In patients with general medical conditions and comorbid chronic MDD (lasting ≥2 years), recurrent MDD, or both, no additional benefi t was seen for combination antidepressant therapy vs SSRI monotherapy. 
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